Our Technology Partners
To address the challenge of enabling the Intravascular Implantable Defibrillator™ (IID) to deliver the same operational performance as its larger, conventional counterparts, InnerPulse has forged exclusive development agreements with,
to date, three technology leaders:
- Greatbatch, Inc. (NYSE: GB)—a leading developer and manufacturer of critical components such as batteries and capacitors used in implantable medical devices and other technically demanding
applications. For InnerPulse, the company is developing an exclusive new generation of components based on its proprietary technology. For more information, visit www.greatbatch.com.
- AMI Semiconductor, Inc. (NASDAQ: AMIS)—a leading developer of low-power, mixed-signal, and wireless implantable medical-semiconductor solutions. The company’s ASIC technology will enable InnerPulse’s IID device to provide
life-saving defibrillator technology will ultra-low-power solutions. For more information, visit www.amis.com.
- Enpath Medical (NASDAQ: NPTH)—a leading developer and manufacturer of stimulation leads and therapy delivery systems for Cardiac Rhythm Management (CRM), Neuromodulation and Interventional Radiology markets. For more information, visit www.enpathmed.com.
Our Investors
To date, InnerPulse has raised $35.2 million through two rounds of private financings. Investors include:
- Delphi Ventures—a private venture-capital firm focusing on early-stage U.S. medical device and biotechnology investments. Founded in 1988, the company has approximately $600 million under management and invested
in more than 125 healthcare companies. For more information, visit www.delphiventures.com.
- Frazier Healthcare Ventures—a venture-capital firm supporting emerging growth companies across the healthcare industry at all stages of development, from incubation to late stage. With more than $1 billion under
management, the firm takes an active role in its investments and has one of the largest healthcare investment teams in the venture-capital community. For more information, visit
www.frazierco.com.
- Johnson & Johnson Development Corporation (JJDC)—the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture-funded healthcare companies. Portfolio companies include
those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics, and consumer products. Organized in 1973, JJDC also leads and manages internal investments in selected promising technologies. For more
information, visit www.jjdevcorp.com.
GO BACK
